1691-P: Clinical Outcomes in Patients with Obesity or Overweight Treated with Semaglutide 2.4 mg—A Real-World Retrospective Cohort Study in the United States (SCOPE 2)

Introduction & Objective: This study assessed changes in clinical outcomes among patients with obesity or overweight treated with semaglutide 2.4mg versus no anti-obesity medications (AOM) in the US. Methods: This retrospective database cohort study used the electronic health records linked to administrative claims from Komodo Health and included patients (≥18 years) with obesity, or overweight with ≥1 obesity-related comorbidity, who started therapy with semaglutide 2.4mg after June 15, 2021 and remained adherent for 12 months or those not treated with any AOM in the same period. Propensity score matching (1:4) was used to address treatment selection bias. Changes in weight from baseline to the end of 12 months follow-up, and proportions of patients achieving ≥5%, ≥10%, and ≥15% weight reduction were compared between the matched cohorts using generalized linear models. Results: Matched cohorts (143 semaglutide 2.4mg patients and 571 no AOM patients) were balanced in baseline characteristics with mean (SD) BMI 39.8 (7.35) kg/m2, mean (SD) age 46 (10.9) years, and 77% were female. At 1-year post-index, semaglutide 2.4mg patients had a significantly greater reduction in weight (−15.0% vs. −1.3%, P<0.001) and a greater proportion of patients achieved a weight reduction ≥5% (83.9% vs 20.1%), ≥10% (74.8% vs. 7.4%), and ≥15% (49.7% vs. 3.7%) (P<0.001 for all three comparisons). Conclusion: In this real-world study, patients with obesity or overweight treated with semaglutide 2.4mg demonstrated a greater, sustained, and clinically relevant reduction in body weight versus those not treated with an AOM. These changes are consistent with those observed in clinical trials. Disclosure W. Michalak: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk, Eli Lilly and Company. A. Fabricatore: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk. B. O Hartaigh: Employee; Novo Nordisk A/S. A. Ruseva: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk. Z. Zhao: None. D. Umashanker: Consultant; Novo Nordisk. Funding Novo Nordisk Inc.